Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude du JNJ-90189892 pour la leucémie myéloïde aiguë ou les néoplasmes myélodysplasiques récidivants ou réfractaires

2 novembre 2026 mis à jour par: Janssen Research & Development, LLC

Une étude de phase 1, la première chez l'homme, sur l'augmentation de la dose du JNJ-90189892 pour la leucémie myéloïde aiguë récidivante ou réfractaire ou les néoplasmes myélodysplasiques

The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS [type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose [RP2CD]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

85

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Concord, Australie, 2139
        • Concord Hospital
      • Melbourne, Australie, 3000
        • Peter MacCallum Cancer Centre
      • Nedlands, Australie, 6009
        • Sir Charles Gairdner Hospital
      • Madrid, Espagne, 28040
        • Hosp Univ Fund Jimenez Diaz
      • Pamplona, Espagne, 31008
        • Clinica Univ. de Navarra
      • Seville, Espagne, 41013
        • Hospital Universitario Virgen Rocio
      • Marseille, France, 13273
        • Institut Paoli-Calmettes
      • Strasbourg, France, 67200
        • CHRU de Strasbourg - Hopital de Hautepierre
      • Toulouse, France, 31100
        • Institut Claudius Regaud

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • A. For Parts 1, 2, and 3: Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Parts 1, 2, and 3: Acute myeloid leukemia (AML) or (b) Parts 1 and 2: Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M); B. For Part 4 only: Previously untreated acute myeloid leukemia (AML) per the WHO 2022 criteria
  • Body weight that is greater than or equals to (>=) 40 kg
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min) computed with the calculator on the national kidney foundation website
  • Participants must have laboratory parameters in the required range

Exclusion Criteria:

  • Has a medical history of clinically significant pulmonary compromise, particularly the current need for supplemental oxygen use to maintain adequate oxygenation
  • Has evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
  • All participants- Has known allergies, hypersensitivity, or intolerance to JNJ-90189892 or its excipients; Parts 3 and 4- Has known allergies, hypersensitivity, or intolerance to venetoclax (VEN), azacitadine (AZA), or their excipients
  • Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-90189892
  • Had a prior or concurrent second malignancy with natural history or treatment likely to interfere with any study endpoints of safety or the efficacy of the study treatment
  • Has known active central nervous system involvement

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: JNJ-90189892: Monotherapy

Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1.

JNJ-90189892 will be administered.

Expérimental: JNJ-90189892: In Combination with Azacitadine (AZA)+ Venetoclax (VEN)

Participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) in Part 3 will receive JNJ-90189892+ AZA+VEN to determine the recommended Phase 2 combination dose (RP2CD). The starting JNJ-90189892 dose regimen in Part 3 will be at least 1 dose level below the highest dose level cleared in Part 1 as determined by the SET. In Part 4 participants with newly diagnosed (ND) AML will receive JNJ-90189892+ AZA+VEN starting from the JNJ-90189892 dose level determined safe in Part 3 by the SET.

JNJ-90189892 will be administered.

AZA will be administered.

VEN will be administered.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants with Adverse events (AEs) by Severity
Délai: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Délai: At least 14 days

DLT is defined as any toxicity that requires discontinuation of treatment, any Grade 5 toxicity; Non-hematologic toxicity (Grade 3 or 4) and Hematologic toxicity.

At least 14 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Serum Concentration of JNJ-90189892
Délai: Up to approximately 2.5 years

Serum samples will be analyzed to determine concentrations of JNJ-90189892.

Up to approximately 2.5 years
Area Under the Curve Over a Dosing Interval (AUC tau) of JNJ-90189892
Délai: Up to approximately 2.5 years

AUC tau is the total observed plasma concentration of JNJ-90189892 in the body during the time between doses. AUCtau of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Maximum Observed Plasma Concentration (Cmax) of JNJ-90189892
Délai: Up to approximately 2.5 years

Cmax is the maximum observed plasma concentration of JNJ-90189892. Cmax of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Minimum Observed Plasma Concentration (Cmin) of JNJ-90189892
Délai: Up to approximately 2.5 years

Cmin is the minimum observed plasma concentration of JNJ-90189892. Cmin of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Number of Participants with Presence of Anti-JNJ-90189892 Antibodies
Délai: Up to approximately 2.5 years

Participants with presence of anti-JNJ-90189892 antibodies will be reported.

Up to approximately 2.5 years
Complete Response (CR) in Acute Myeloid Leukemia (AML)
Délai: Up to approximately 2.5 years

CR is achieved when a participant has a best response of CR (including complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ENL) 2022 criteria.

Up to approximately 2.5 years
Overall Response (OR) in Myelodysplastic Neoplasms (MDS)
Délai: Up to approximately 2.5 years

OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria.

Up to approximately 2.5 years
Complete Response in MDS
Délai: Up to approximately 2.5 years

CR is achieved when a participant has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria.

Up to approximately 2.5 years
Duration of Response (DOR)
Délai: Up to approximately 2.5 years

DOR is defined for responsders only, as time from date of initial documentation of a response to the first documented evidence of no reponse, disease progression, relapse, initation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first.

Up to approximately 2.5 years
Time to Response (TTR)
Délai: Up to approximately 2.5 years

TTR is defined for responders, as the time from the first dose of study drug to first qualifying response.

Up to approximately 2.5 years
Number of Participants Achieving Transfusion Independence
Délai: Up to approximately 2.5 years

Transfusion independence is defined as the absence of red blood cell (RBC) and platelet transfusions for 8 weeks or longer after starting study treatment for participants with AML and 16 weeks or longer for participants with MDS.

Up to approximately 2.5 years
Part 4 Only: Overall Survival (OS)
Délai: Up to approximately 2.5 years

OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause.

Up to approximately 2.5 years
Part 4 Only: Event-Free Survival (EFS)
Délai: Up to approximately 2.5 years

EFS is defined as the time from the date of first dose of study treatment to the date of first documented evidence of treatment failure, relapse or death due to any cause, whichever occurs first.

Up to approximately 2.5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 mars 2025

Achèvement primaire (Estimé)

5 août 2027

Achèvement de l'étude (Estimé)

9 février 2028

Dates d'inscription aux études

Première soumission

18 octobre 2024

Première soumission répondant aux critères de contrôle qualité

18 octobre 2024

Première publication (Réel)

21 octobre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 90189892AML1001
  • 2024-514341-10-00 (Identificateur de registre: EUCT number)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner